20 Results for "

hSGLT2

" in MedChemExpress (MCE) Product Catalog:
Products (20)

20 Results for "hSGLT2" in MCE Product Catalog:

  • Isoforms Recommended:
47
47 Publications Verification
Cat. No.: HY-10451
CAS No.: 842133-18-0
Purity:  99.70%
Synonyms: JNJ 28431754
Target:  

SGLT

Research Areas:  

Metabolic Disease Cancer

Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
loading...
    loading...
47
47 Publications Verification
Cat. No.: HY-I0383
CAS No.: 928672-86-0
Synonyms: JNJ 28431754 hemihydrate
Target:  

SGLT

Research Areas:  

Metabolic Disease Cancer

Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-N0143
CAS No.: 60-81-1
Synonyms: Floridzin
Phlorizin (Floridzin) is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities [2] .
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-N0143A
CAS No.: 7061-54-3
Synonyms: Floridzin dihydrate
Phlorizin (Floridzin) dihydrate is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin dihydrate promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin dihydrate reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin dihydrate induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin dihydrate also exhibits antibacterial, anti-inflammatory and neuroprotective activities [2] .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15461
CAS No.: 1210344-57-2
Purity:  99.92%
Synonyms: PF-04971729
Target:  

SGLT

Research Areas:  

Metabolic Disease

Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus [2].
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-15461A
CAS No.: 1210344-83-4
Purity:  99.84%
Synonyms: PF-04971729 L-pyroglutamic acid
Target:  

SGLT

Research Areas:  

Metabolic Disease

Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus [2].
loading...
    loading...
Cat. No.: HY-14945
CAS No.: 442201-24-3
Purity:  99.81%
Synonyms: GSK189075
Target:  

SGLT

Research Areas:  

Metabolic Disease

Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
loading...
    loading...
Cat. No.: HY-15461R
CAS No.: 1210344-57-2
Synonyms: PF-04971729 (Standard)
Research Areas:  

Metabolic Disease

Ertugliflozin (Standard) is the analytical standard of Ertugliflozin. This product is intended for research and analytical applications. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus [2].
loading...
    loading...
Cat. No.: HY-137145
CAS No.: 1408245-02-2
Target:  

SGLT

Research Areas:  

Others

Galacto-dapagliflozin is a selective inhibitor for hSGLT2 with Ki of 25 nM .
loading...
    loading...
Cat. No.: HY-14810
CAS No.: 647834-15-9
Synonyms: AVE-2268
Target:  

SGLT

Research Areas:  

Metabolic Disease

Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .
loading...
    loading...
Cat. No.: HY-114308
CAS No.: 1240305-17-2
Target:  

SGLT

Research Areas:  

Metabolic Disease

SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment .
loading...
    loading...
Cat. No.: HY-10451R
CAS No.: 842133-18-0
Synonyms: JNJ 28431754 (Standard)
Research Areas:  

Metabolic Disease Cancer

Canagliflozin (Standard) is the analytical standard of Canagliflozin. This product is intended for research and analytical applications. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
loading...
    loading...
Cat. No.: HY-112807
CAS No.: 2247314-23-2
Target:  

SGLT

Research Areas:  

Metabolic Disease

SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively .
loading...
    loading...
Cat. No.: HY-124664
CAS No.: 957772-01-9
Target:  

SGLT

Research Areas:  

Metabolic Disease

TP0438836 (compound 30b) is a SGLT1 inhibitor, with IC50 values ​​of 28 nM and 7 nM for hSGLT1 and hSGLT2, respectively. TP0438836 can be used in diabetes research .
loading...
    loading...
Cat. No.: HY-165438
CAS No.: 360775-96-8
Target:  

SGLT

Research Areas:  

Others

Sergliflozin-A is a compound used to inhibit type 2 diabetes. It can inhibit glucose transporters in the kidney, competitively inhibit hSGLT1 and hSGLT2, and mutations at different sites have different effects on its inhibitory effect.
loading...
    loading...
Cat. No.: HY-10451S2
Synonyms: JNJ 28431754-d6
Canagliflozin-d6 is the deuterium labeled Canagliflozin . Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively [2].
loading...
    loading...
Cat. No.: HY-15461S
CAS No.: 1298086-22-2
Synonyms: PF-04971729-d5
Ertugliflozin-d5 is the deuterium labeled Ertugliflozin . Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 [2]. Has the potential for the treatment of type 2 diabetes mellitus .
loading...
    loading...
Cat. No.: HY-15461S1
Synonyms: PF-04971729-d9
Ertugliflozin-d9 is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus [2].
loading...
    loading...
Cat. No.: HY-N0143R
CAS No.: 60-81-1
Synonyms: Floridzin (Standard)
Phlorizin (Floridzin) (Standard) is the analytical standard of Phlorizin. This product is intended for research and analytical applications. Phlorizin is an orally active non-selective sodium-glucose cotransporter (SGLT) inhibitor, with an IC50 of 0.04 μM and a Ki of 39 nM against hSGLT2, and an IC50 of 0.17 μM and a Ki of 0.31 μM against hSGLT1. Phlorizin promotes GLUT4 translocation, inhibits gluconeogenesis and promotes glycogen synthesis by activating the PI3K/Akt/mTOR pathway. Phlorizin reduces DNA damage and apoptosis (apoptosis) by inhibiting the NF-κB inflammatory pathway. Phlorizin induces apoptosis via activating the Caspase pathway by antagonizing the JAK/STAT3 and PCK pathways. Phlorizin also exhibits antibacterial, anti-inflammatory and neuroprotective activities [2] .
loading...
    loading...
Cat. No.: HY-166548S
CAS No.: 1233515-93-9
Synonyms: GSK189075-d7
Remogliflozin etabonate-d7 (GSK189075-d7) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
loading...
    loading...
  • 1